Last updated: February 20, 2026
What is NDC 57237-0154?
NDC 57237-0154 corresponds to Bupropion Hydrochloride Extended-Release (SR) and Bupropion Hydrochloride Extended-Release (SR) + Naltrexone (Extended-Release). This formulation targets the treatment of obesity and weight management, combining bupropion (an antidepressant and smoking cessation aid) with naltrexone (an opioid antagonist).
Market Overview
Product Status and Approvals
- Approved Uses: Indication includes obesity management and weight loss, often through FDA approval of marketed combination drugs.
- Key Competitors:
- Wegovy (semaglutide): Approved for obesity; sales exceeded $1 billion in 2022.
- Qsymia (phentermine/topiramate ER): Developed as a weight management medication.
- Contrave (naltrexone/bupropion): Similar formulation; FDA-approved for weight loss.
- Market Entry: The combination of bupropion and naltrexone, marketed as Contrave, has a well-established presence. The specific NDC indicates a newer formulation or generic equivalent.
Market Size and Growth
- The global anti-obesity pharmacotherapy market is projected to reach $3.3 billion by 2025, growing at a CAGR of approximately 10% from 2021 (ResearchandMarkets, 2022).
- In the U.S., weight management drugs account for $1.4 billion in sales annually (IQVIA, 2022).
- The replacement of branded formulations with generics or biosimilars influences pricing and penetration strategies.
Price Analysis
Current Pricing Data
- Brand Name (Contrave):
- Average wholesale price (AWP): $250–$350 per month (GoodRx, 2023).
- Insurance reimbursements often lower this figure.
- Generic equivalents:
- Similar formulations priced between $50–$150 per month.
- New formulations or NDC-specific products:
- May command premiums, especially if backed by recent clinical data or expanded indications.
- Estimated retail price: $200–$300 per month in the U.S.
Price Projection Factors
- Regulatory approval and reimbursement policies: Positive decisions increase market access, potentially raising prices.
- Market penetration: Entry of generics and biosimilars tends to decrease prices over time.
- Manufacturing costs and supply chain: Cost reductions can pressure prices downward.
- Competitive landscape: Presence of newer therapies like semaglutide-based drugs affects premium pricing plans.
Future Price Trends
Based on historical data, the price for branded obesity medications tends to decline 10–20% within two years of generic launches. If NDC 57237-0154 is introduced as a generic or biosimilar, expect initial prices in the $150–$200 range, decreasing toward $50–$100 over 3–5 years.
Revenue and Market Share Projections
| Year |
Estimated Market Size |
Projected Market Share |
Estimated Revenue (USD) |
| 2023 |
$3.3 billion (global) |
0.2% |
$6.6 million |
| 2024 |
$3.63 billion |
0.3% |
$10.9 million |
| 2025 |
$3.96 billion |
0.5% |
$19.8 million |
Assumptions: Incremental market share growth driven by formulary inclusion and clinical acceptance.
Key Drivers and Risks
Drivers:
- Increased obesity prevalence.
- Expanding indications and combination therapies.
- Insurance reimbursement expanding to cover newer formulations.
Risks:
- Regulatory hurdles delaying approval or reimbursement.
- Competitive pressure from high-efficacy drugs like semaglutide.
- Patent expiration or unfavorable legal decisions.
Summary
NDC 57237-0154 operates in a competitive, fast-growing market tied to obesity therapeutics. Its pricing will largely depend on approval status, clinical efficacy, and market dynamics, including generic entry and competing drugs.
Key Takeaways
- The obesity treatment market is projected to grow at 10% CAGR, reaching over $3 billion globally.
- Prices for similar formulations range from $50 to $350 monthly, with newer products commanding higher premiums initially.
- Entry of generics is likely to reduce prices by up to 20% within two years.
- Market share projections suggest moderate growth, with revenues potentially reaching $20 million by 2025.
- Regulatory approvals, reimbursement policies, and competitive landscape will influence actual pricing and market penetration.
FAQs
1. What clinical data support the use of NDC 57237-0154?
Clinical trials demonstrate modest weight loss benefits when combined with lifestyle interventions, comparable to existing therapies like Contrave.
2. How does the pricing of this formulation compare to competitors?
It is positioned similarly to branded Contrave, with potential for higher prices if supported by unique clinical or formulation advantages.
3. When could generics or biosimilars impact prices?
Likely within 2–5 years of patent expiry or regulatory approval of alternatives.
4. What regulatory challenges could affect market entry?
FDA approval delays, requirement for additional clinical data, or restricted indications could affect market timing and pricing strategies.
5. How does the market outlook affect investment in this drug?
The expanding obesity market and favorable reimbursement policies support investment, but high competition and price erosion risks remain.
References
- ResearchandMarkets. (2022). Global Obesity Pharmacotherapy Market Outlook.
- IQVIA. (2022). U.S. Prescription Drug Market Data.
- GoodRx. (2023). Price Comparisons for Contrave.
